In Vitro and In Vivo Characterization of Temoporfin-Loaded Pegylated Plga Nanoparticles for Use in Photodynamic Therapy

Abstract

The objective of this study was to develop angiopoietin-1 (Ang1)-expressing genetically modified human adipose tissue derived stem cells (hASCs) for myocardial therapy. For this, an efficient gene delivery system using recombinant baculovirus complexed with cell penetrating transactivating transcriptional activator TAT peptide/deoxyribonucleic acid nanoparticles (Bac-NP), through ionic interactions, was used. It was hypothesized that the hybrid Bac- NP(Ang1) system can efficiently transduce hASCs and induces favorable therapeutic effects when transplanted in vivo. To evaluate this hypothesis, a rat model with acute myocardial infarction and intramyocardially transplanted Ang1-expressing hASCs (hASC-Ang1), genetically modified by Bac-NP(Ang1), was used. Ang1 is a crucial pro-angiogenic factor for vascular maturation and neovasculogenesis. The released hAng1 from hASC-Ang1 demonstrated profound mitotic and anti-apoptotic activities on endothelial cells and cardiomyocytes. The transplanted hASC-Ang1 group showed higher cell retention compared to hASC and control groups. A significant increase in capillary density and reduction in infarct sizes were noted in the infarcted hearts with hASC-Ang1 treatment compared to infarcted hearts treated with hASC or the untreated group. Furthermore, the hASC-Ang1 group showed significantly higher cardiac performance in echocardiography (ejection fraction 46.28% ± 6.3%, P < 0.001 versus control, n = 8) than the hASC group (36.35% ± 5.7%, P < 0.01, n = 8), 28 days post-infarction. The study identified Bac-NP complex as an advanced gene delivery vehicle for stem cells and demonstrated its potential to treat ischemic heart disease with high therapeutic index for combined stem cell-gene therapy strategy.

Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells

“…1A). Covalently linked hydrophilic PEG blocks modify PLGA, producing smaller particles (Rojnik et al, 2012). All NP formulations were of low polydispersity index ranging from 0.26 to 0.39.…”

In Vitro IFN-α Release From IFN-α- and Pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and Pegylated poly(lactic-co-glycolic acid) Nanoparticles

“…A number of liposome encapsulated anticancer and anti-microbial agents have entered routine clinical arena. Another class of promising nanoparticles for encapsulation are the FDA approved biocompatible and biodegradable polymers such as poly (D,L-lactic-co-glycolic acid) (PLGA), poly (D,L-lacticacid) (PLA), poly (D,L-lactic-co-glycolic acid)-polyethylene glycol (PEG-PLGA) [3,4].…”

Paclitaxel-loaded poly(glycolide-co-&epsilon;-caprolactone)-b-D-&alpha;-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy

“…31,32 These drawbacks can be overcome by introduced D-α-tocopheryl polyethylene glycol (PEG) 2000 succinate (TPGS 2k ) to PGA, PCL, and PGA-co-PCL. 13,33 TPGS 2k , a water-soluble derivative of natural vitamin E, is formed by esterification of vitamin E succinate with PEG 2000. The chemical structure of TPGS is hydrophilic polar head group and lipophilic alkyl tail.…”